Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Operating Leases (2019 - 2025)

Integra Lifesciences Holdings (IART) has disclosed Operating Leases for 7 consecutive years, with $177.1 million as the latest value for Q4 2025.

  • Quarterly Operating Leases rose 6.08% to $177.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $177.1 million through Dec 2025, up 6.08% year-over-year, with the annual reading at $177.1 million for FY2025, 6.08% up from the prior year.
  • Operating Leases hit $177.1 million in Q4 2025 for Integra Lifesciences Holdings, up from $174.8 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $184.2 million in Q2 2024 to a low of $87.8 million in Q1 2022.
  • Historically, Operating Leases has averaged $153.6 million across 5 years, with a median of $167.9 million in 2023.
  • Biggest five-year swings in Operating Leases: fell 19.77% in 2022 and later surged 95.55% in 2023.
  • Year by year, Operating Leases stood at $90.3 million in 2021, then skyrocketed by 90.46% to $172.0 million in 2022, then rose by 5.86% to $182.1 million in 2023, then fell by 8.35% to $166.9 million in 2024, then rose by 6.08% to $177.1 million in 2025.
  • Business Quant data shows Operating Leases for IART at $177.1 million in Q4 2025, $174.8 million in Q3 2025, and $159.3 million in Q2 2025.